Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Non-Current Deferred Tax Liability (2022 - 2025)

InMed Pharmaceuticals' Non-Current Deferred Tax Liability history spans 3 years, with the latest figure at $20000.0 for Q2 2025.

  • For Q2 2025, Non-Current Deferred Tax Liability changed N/A year-over-year to $20000.0; the TTM value through Jun 2025 reached $20000.0, changed N/A, while the annual FY2025 figure was $20000.0, N/A changed from the prior year.
  • Non-Current Deferred Tax Liability reached $20000.0 in Q2 2025 per INM's latest filing, down from $211266.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $211266.0 in Q2 2023 to a low of $20000.0 in Q2 2025.
  • Average Non-Current Deferred Tax Liability over 3 years is $101024.0, with a median of $71806.0 recorded in 2022.
  • The largest YoY upside for Non-Current Deferred Tax Liability was 194.22% in 2023 against a maximum downside of 194.22% in 2023.
  • A 3-year view of Non-Current Deferred Tax Liability shows it stood at $71806.0 in 2022, then surged by 194.22% to $211266.0 in 2023, then plummeted by 90.53% to $20000.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Non-Current Deferred Tax Liability are $20000.0 (Q2 2025), $211266.0 (Q2 2023), and $71806.0 (Q2 2022).